Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig
JM Kremer, R Westhovens, M Leon… - … England Journal of …, 2003 - Mass Medical Soc
Background Effective new therapies are needed for rheumatoid arthritis. Current therapies
target the products of activated macrophages; however, T cells also have an important role …
target the products of activated macrophages; however, T cells also have an important role …
Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig.
JM Kremer, R Westhovens, M Leon… - The New England …, 2003 - europepmc.org
Background Effective new therapies are needed for rheumatoid arthritis. Current therapies
target the products of activated macrophages; however, T cells also have an important role …
target the products of activated macrophages; however, T cells also have an important role …
Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig
JM Kremer, R Westhovens, M Leon… - The New England …, 2003 - pubmed.ncbi.nlm.nih.gov
Background Effective new therapies are needed for rheumatoid arthritis. Current therapies
target the products of activated macrophages; however, T cells also have an important role …
target the products of activated macrophages; however, T cells also have an important role …
[PDF][PDF] Treatment of Rheumatoid Arthritis by Selective Inhibition of T-Cell Activation with Fusion Protein CTLA4Ig
JM Kremer, R Westhovens, M Leon… - N Engl J Med, 2003 - academia.edu
Effective new therapies are needed for rheumatoid arthritis. Current therapies target the
products of activated macrophages; however, T cells also have an important role in …
products of activated macrophages; however, T cells also have an important role in …
Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig
JM Kremer, R Westhovens, M Leon… - New England Journal of …, 2003 - elibrary.ru
Fewer serious adverse events were reported in the group given 10 mg of CTLA4Ig per
kilogram than in the group given 2 mg of CTLA4Ig per kilogram or the placebo group (Table …
kilogram than in the group given 2 mg of CTLA4Ig per kilogram or the placebo group (Table …
[PDF][PDF] Treatment of Rheumatoid Arthritis by Selective Inhibition of T-Cell Activation with Fusion Protein CTLA4Ig
JM Kremer, R Westhovens, M Leon… - N Engl J …, 2003 - researchgate.net
Effective new therapies are needed for rheumatoid arthritis. Current therapies target the
products of activated macrophages; however, T cells also have an important role in …
products of activated macrophages; however, T cells also have an important role in …
[引用][C] Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig
JM KREMER - N Engl J Med, 2003 - cir.nii.ac.jp
[引用][C] Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig
JM KREMER, R WESTHOVENS… - The New England …, 2003 - pascal-francis.inist.fr
Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion
protein CTLA4Ig CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic …
protein CTLA4Ig CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic …
[引用][C] Treatment of Rheumatoid Arthritis by Selective Inhibition of T-Cell Activation with Fusion Protein CTLA4Ig
JJM Kremer, R Westhovens, M Leon… - The New England …, 2003 - difusion.ulb.ac.be
[PDF][PDF] Treatment of Rheumatoid Arthritis by Selective Inhibition of T-Cell Activation with Fusion Protein CTLA4Ig
JM Kremer, R Westhovens, M Leon… - N Engl J Med, 2003 - academia.edu
Effective new therapies are needed for rheumatoid arthritis. Current therapies target the
products of activated macrophages; however, T cells also have an important role in …
products of activated macrophages; however, T cells also have an important role in …
